Roche/Ipsen Plan 2010 Filing For Once-Weekly GLP-1 Analog
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III studies pitting once-weekly taspoglutide against Lilly's Byetta and Merck's Januvia commence in the second half.